Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kathalene Keller Riney

Nurse Practitioner, Family Evansville, IN Nurse Practitioner

NPI 1457786642 CMS profile 10983442

220 E Virginia St, Evansville, IN 47711

Open in the dashboard

General payments

$382,546

1,205 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathalene Keller Riney of Evansville, IN is reported in the CMS Open Payments database as having received $382,546 across 1,205 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $94,151 351
2024 General $73,636 251
2023 General $128,563 282
2022 General $26,341 156
2021 General $59,855 165

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathalene Keller Riney
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kathalene Keller Riney were reported at $94,151. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kathalene Keller Riney Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $59,855 $124 $35–$379 $132
2022 $26,341 $141 $44–$430 $149
2023 $128,563 $154 $49–$476 $160
2024 $73,636 $165 $51–$504 $164
2025 $94,151 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $343,491 660 payments
  2. Phathom Pharmaceuticals, Inc. $24,899 52 payments
  3. Allergan Inc. $4,050 4 payments
  4. Amgen Inc. $1,139 69 payments
  5. AstraZeneca Pharmaceuticals LP $1,048 23 payments
  6. Novo Nordisk Inc $812 44 payments
  7. E.R. Squibb & Sons, L.L.C. $687 39 payments
  8. GlaxoSmithKline, LLC. $593 24 payments
  9. Otsuka America Pharmaceutical, Inc. $525 26 payments
  10. Lilly USA, LLC $506 31 payments
  11. Other $4,797 233 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $340,829 208 payments
  2. Travel and Lodging $21,765 124 payments
  3. Food and Beverage $18,209 863 payments
  4. Consulting Fee $1,340 4 payments
  5. Education $403 6 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $208,721 342 payments
  2. VRAYLAR Neuroscience $77,576 104 payments
  3. UBRELVY $56,768 176 payments
  4. VOQUEZNA $24,886 51 payments
  5. QULIPTA $13,569 80 payments
  6. SOTYKTU $687 39 payments
  7. AIRSUPRA $674 11 payments
  8. REXULTI $510 25 payments
  9. TRELEGY ELLIPTA $495 23 payments
  10. Otezla $471 32 payments
  11. Other $9,526 520 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

2,610

Median for Nurse Practitioner: 389

Drug cost

$368,857

Median for Nurse Practitioner: $21,885

Branded share of claims

27.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 58 $117,305
Vraylar Cariprazine Hcl Brand 40 $55,478
Farxiga Dapagliflozin Propanediol Brand 34 $42,719
Mounjaro Tirzepatide Brand 31 $39,603
Jardiance Empagliflozin Brand 25 $26,888
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 14 $17,960
Eliquis Apixaban Brand 17 $16,619
Linzess Linaclotide Brand 11 $14,251
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 15 $4,733
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 14 $3,160

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$69,670

Of which drugs: $22,522

Medicare patients

127

Average age 69

Services billed

3,667

87 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 55%
Depression 39%
Diabetes 24%
Ischemic heart disease 20%
Chronic kidney disease 15%
COPD 15%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ketorolac tromethamine, per 15 mg J1885 Office 12 110 $62
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 30 590 $49
Injection, ceftriaxone sodium, per 250 mg J0696 Office 13 44 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 41 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$52,386 40 —
VOQUEZNA
$13,595 — —
UBRELVY
$3,532 — —
QULIPTA
$1,874 — —
AIRSUPRA
$271 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 41 with Patron

Records

1,205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record